Evidence map›Paper›PMID 40467586›Full record

ArticleNature communications2025

FXYD2 marks and regulates maturity of β cells via ion channel-mediated signal transduction.

Clarissa Tacto, Meghan Tahbaz, Andrew Salib, Shudi Wang, Fritz Cayabyab, Jinhyuk Choi, Kiyoka Kim, Yu Hamba, Harvey Perez, Paul D Gershon and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. FXR and BET signaling orchestrate to protect β cells.bioRxiv : the preprint server for biology · 2026
    Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Clarissa TactoThe Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, CA, USA.ORCID http://orcid.org/0009-0003-2461-0268
Meghan TahbazThe Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, CA, USA.
Andrew SalibThe Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, CA, USA.
Shudi WangThe Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, CA, USA.
Fritz CayabyabThe Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, CA, USA.
Jinhyuk ChoiThe Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, CA, USA.
Kiyoka KimThe Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, CA, USA.ORCID http://orcid.org/0009-0002-3381-9058
Yu HambaThe Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, CA, USA.
Harvey PerezThe Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, CA, USA.
Paul D GershonDepartment of Molecular Biology and Biochemistry, University of California Irvine, Irvine, CA, USA.ORCID http://orcid.org/0000-0002-4904-9193
Robert DamoiseauxDepartment of Bioengineering in the Samueli School of Engineering, University of California Los Angeles, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0002-7611-7534
Tae Gyu OhDepartment of Oncology Science, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.ORCID http://orcid.org/0000-0002-2756-3546
Eiji YoshiharaThe Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, CA, USA. eiji.yoshihara@lundquist.org.ORCID http://orcid.org/0000-0001-6324-6495

Funding

Spatiotemporal regulation of human islet organogenesisR01DK136888 · NIDDK · LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER · PI Eiji Yoshihara · 2024 to 2026
$1.8M
LTQ Velos Pro mass spectrometer with ETD and other optionsS10OD016328 · OD · UNIVERSITY OF CALIFORNIA-IRVINE · PI GERSHON, PAUL D · 2013 to 2013
$374k
NIDDK NIH HHS R01 DK136888NIH HHS S10 OD016328U.S. Department of Health & Human Services | National Institutes of Health (NIH) R01DK136888
6 · The paper itself

Abstract

Human pancreatic islets regulate organ development and metabolic homeostasis, with dysfunction leading to diabetes. Human pluripotent stem cells (hPSCs) provide a potential alternative source to cadaveric human pancreatic islets for replacement therapy in diabetes. However, human islet-like organoids (HILOs) generated from hPSCs in vitro often exhibit heterogeneous immature phenotypes such as aberrant gene expression and inadequate insulin secretion in response to glucose. Here we show that FXYD Domain Containing Ion Transport Regulator 2 (FXYD2) marks and regulates functional maturation and heterogeneity of generated HILOs, by controlling the β cell transcriptome necessary for glucose-stimulated insulin secretion (GSIS). Despite its presence in mature β cells, FXYD2 is diminished in hPSC-derived β-like cells. Mechanistically, we find that FXYD2 physically interacts with SRC proto-oncogene, non-receptor tyrosine kinase (SRC) protein to regulate FXYD2-SRC-TEAD1 signaling to modulate β cell transcriptome. We demonstrate that FXYD2

Indexed as

Insulin-Secreting CellsIon ChannelsMembrane ProteinsSignal TransductionAnimalsCell DifferentiationDiabetes Mellitus, ExperimentalDNA-Binding ProteinsGlucoseHumansInsulin SecretionIslets of LangerhansMaleMiceNuclear ProteinsOrganoidsDNA-Binding ProteinsGlucoseIon ChannelsMAS1 protein, humanMembrane ProteinsNuclear ProteinsProto-Oncogene Massrc-Family KinasesTranscription Factors

Identifiers

PMID40467586
PMCPMC12137567

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.